Dr. White currently provides consulting services on antimicrobial drug discovery and development to the biotechnology industry. He is Chairman of the Board of directors of F2G (a UK antifungal company) and an independent Director for INDEL (a Canadian antibacterial target company), and also serves on the Scientific Advisory Boards of several privately held Biotechnology companies. His career started in pharmaceutical research, where he occupied positions of increasing responsibility at Lepetit (in Italy), Glaxo (in England), Lederle (in the USA), and finally at Bristol-Myers Squibb, where he was Vice President of Infectious Disease Drug Discovery for 12 years. In 1997 he moved to biotech, taking a position at Versicor in California where he became Chief Scientific Officer. In the ensuing eight years he played an important role in the licensing in of Dalbavancin and Anidulafungin, helping take Versicor public and merging with Biosearch Italia. The merged entity became Vicuron Pharmaceuticals, which was sold for $1.9 billion to Pfizer in 2005. Dr. White's research interests are on the mechanism of action of and resistance to antimicrobial drugs, and the special role that natural products have played in treating infectious diseases. He received his B.Sc. in biochemistry from the University of Manchester Institute of Science and Technology and his D.Phil. in biochemistry from the University of Oxford.